Page Changed: Insulin for Type 2 Diabetes
Added the following:
Tresiba, a longer acting insulin was approved in late September of 2015. Basaglar, a biosimilar version of Lantus will not be sold in the U.S. until 2017,
You can learn more about the new basal insulins in these blog posts which go into the properties of each extensively:
Toujeo, a More Concentrated Version of Lantus
The Newly Approved Basal Insulin Tresiba's Label is Disappointing.